Fielder and Oppenheim's Secret Holmes Film Lands at Telluride
A documentary about Elizabeth Holmes by Nathan Fielder and Lance Oppenheim surfaced without warning at Telluride on Sunday night, built on extensive access to the Theranos founder.
Nathan Fielder and Lance Oppenheim premiered an undisclosed documentary about Theranos founder Elizabeth Holmes, "You Can See Everything," as a secret screening at the Telluride Film Festival on Sunday night, with the film built on extensive access to Holmes.
The Telluride Film Festival keeps a handful of slots off its printed program every year, and on Sunday night one of them turned out to hold the most talked-about documentary of the season. "You Can See Everything," directed by Nathan Fielder and Lance Oppenheim, screened as a secret film and left the audience audibly rattled. Its subject is Elizabeth Holmes, the founder of the failed blood-testing company Theranos, and the film is built on what TechCrunch described as generous access to her.
That access is the story. Holmes has been one of the most photographed and least heard-from figures in modern Silicon Valley history — a face on magazine covers, then a face in court sketches, and then largely absent from the record on her own terms. A documentary made with her participation, rather than around her, is a different object entirely from the Theranos coverage that came before it.
Why a secret screening is a distribution strategy
Telluride is unusual among major festivals in that it does not publish its full lineup in advance. Films arrive in the Colorado mountains and are revealed to a small, concentrated audience of critics, programmers, and — crucially — acquisitions executives. A secret slot amplifies that: nobody arrives with a formed opinion, nobody has read a review, and the reaction in the room is the only data point that exists.
For a documentary without a distributor attached, that is close to an ideal auction environment. The buyers for a high-profile nonfiction title are a familiar group: the streaming platforms that have built documentary brands, the specialty theatrical labels, and the premium cable outlets. All of them staff Telluride. A film that stuns a room there begins its sales process with leverage that a conventional, pre-announced premiere rarely generates.
The secrecy also solved a practical problem. A Holmes documentary announced months ahead would have attracted a wave of coverage before a single frame was seen, and much of that coverage would have been about whether the filmmakers were rehabilitating her. Withholding the title until the lights went down deferred that argument until people had actually watched the thing.
The Fielder-Oppenheim pairing sets expectations
The names on the film matter as much as the name in the title. Nathan Fielder works in a register that treats documentary form itself as unstable — where the line between what is staged and what is real is the point, not an accident. Lance Oppenheim is a documentarian drawn to closed worlds and to subjects whose self-presentation is part of the story.
Put those sensibilities together on Elizabeth Holmes and the result is unlikely to be a conventional rise-and-fall recap. The Theranos story has already been told in book form, in podcast form, in a network documentary and in a prestige drama series. What has not existed is a film in which Holmes is a participant who can be observed constructing her own account in real time. That is the territory this pairing tends to work in.
It also raises the question every documentary built on access has to answer: what did the subject get in exchange? Nothing in the reporting so far indicates the terms of Holmes's participation, and the filmmakers have not detailed them publicly. That will be one of the first things asked of the film when it reaches a wider audience.
The ethics fight that arrives with the film
Access documentaries about disgraced figures land in a well-worn controversy. Critics argue that the camera's presence and the subject's cooperation inevitably soften the account. Defenders argue that hearing a subject speak at length is more damning than any narrator could be, and that the audience is capable of judging for itself.
Holmes is a particularly sharp test case. Theranos raised hundreds of millions of dollars on claims about blood testing that did not hold up, and the fallout touched patients who received results from a system that could not deliver what was advertised. Any film that gives her sustained screen time will be measured against that harm. Whether "You Can See Everything" treats that as its central subject or as background will determine how the reception goes once it moves beyond a festival audience primed for a surprise.
Where this sits in the tech-scandal documentary boom
Critics argue that the camera's presence and the subject's cooperation inevitably soften the account.
Silicon Valley collapse stories have become a durable content category. Failed startups, crypto blowups and founder trials have supplied streaming platforms with a steady run of documentary and scripted material, because the arc is legible — charisma, capital, unraveling — and the archival footage is abundant. Founders in that era filmed themselves constantly.
What has changed is scarcity. There are only so many first-tier scandals, and most have been adapted more than once. A genuinely new element — a subject who talks — is the rarest asset in the category, which is why the Telluride reaction traveled fast.
The broader market backdrop is not especially generous to speculative content spending right now. Broad equity benchmarks closed mixed on Friday, Sept. 4, with the S&P 500 tracker (NYSEARCA: SPY) at $770.23, down 0.38% on the day, the Nasdaq 100 tracker (NASDAQ: QQQ) at $719.00, up 0.19%, and the Dow tracker (NYSEARCA: DIA) at $534.12, down 0.52%. Streaming buyers have spent the past several years narrowing what they pay up for. A documentary that generates a festival-floor reaction is precisely the kind of title that still clears that bar, because the marketing writes itself.
What to watch next
Three things will define the film's next few weeks. First, whether a distributor is announced and on what scale of release — a theatrical run signals awards intent, a straight streaming pickup signals volume play. Second, whether the film travels to the fall festival circuit, which would extend the review cycle and build the case for year-end consideration. Third, whether Holmes or her representatives respond publicly to how she is portrayed, which would tell the audience a great deal about what the filmmakers actually captured.
Until then, the only firm facts are the ones from the room: a title nobody expected, two directors whose work distrusts easy narrative, a subject who agreed to be filmed, and an audience that walked out talking.
Frequently asked questions
What is "You Can See Everything"?
It is a documentary about Elizabeth Holmes, the founder of the failed blood-testing company Theranos, directed by Nathan Fielder and Lance Oppenheim. It premiered as an unannounced secret screening at the Telluride Film Festival on Sunday night. The film was made with what has been described as generous access to Holmes herself, making it distinct from prior Theranos accounts.
Why was the premiere kept secret?
Telluride does not publish its complete lineup in advance and reserves slots for unannounced titles. Keeping a high-profile subject like Holmes under wraps prevented a pre-emptive news cycle about the film's premise and concentrated the first reaction among critics and acquisitions executives in the room, which is useful leverage for a documentary that has not yet announced a distributor.
Who are Nathan Fielder and Lance Oppenheim?
Nathan Fielder is a filmmaker and performer known for work that deliberately blurs the boundary between staged and documentary material. Lance Oppenheim is a documentarian who focuses on closed communities and subjects whose self-presentation forms part of the story. Their collaboration suggests the Holmes film is unlikely to follow a conventional rise-and-fall documentary structure.
Does the film have a distributor?
No distributor had been announced at the time of the Telluride screening. Festival premieres of this kind typically initiate a sales process involving streaming platforms, specialty theatrical labels and premium cable outlets, all of which send acquisitions staff to Telluride. A strong first-audience reaction generally improves the terms a documentary can command.
Why is an access documentary about Holmes controversial?
Documentaries built on a disgraced subject's cooperation raise the question of what the subject received in return and whether participation softens the account. Theranos raised substantial capital on blood-testing claims that failed, with consequences for patients. Any film giving Holmes sustained screen time will be judged on how it handles that harm. The terms of her participation have not been made public.
What happens to the film next?
The immediate markers are whether a distributor is announced and whether the release is theatrical or streaming-first, whether the film continues on the autumn festival circuit to extend its review cycle, and whether Holmes or her representatives comment publicly on the portrayal. Each of those would clarify both the commercial plan and how the film actually treats its subject.
Sources
Photo: Tima Miroshnichenko · Pexels Licence — source
